Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Endostar + chemotherapy (Simcere Pharmaceutical Group, 4c880a)
- Development stage
- Unknown
- Lead developer
- Simcere Pharmaceutical Group
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
Endostar + chemotherapy is a combination therapeutic regimen consisting of the recombinant human endostatin, Endostar, and a standard chemotherapy backbone (typically including methotrexate, cisplatin, doxorubicin, and ifosfamide). Developed by Shandong Simcere-Medgenn Bio-pharmaceutical, Endostar is a biologic anti-angiogenic agent produced in *Escherichia coli*. It features a modified N-terminal nine-amino acid sequence (MGGSHHHHH) that improves its stability and solubility compared to native endostatin. The regimen is primarily investigated for the treatment of osteosarcoma, where Endostar's inhibition of the vascular endothelial growth factor (VEGF) pathway and the Wnt/β-catenin signaling pathway complements the cytotoxic effects of chemotherapy. Endostar was previously approved in China in 2005 for non-small cell lung cancer.
- Other names
- Recombinant human endostatin + chemotherapy
02
Targets
DNATOP2A (DNA topoisomerase II)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)FGF2DHFR (Dihydrofolate reductase)GPC (Lassa virus glycoprotein complex)ITGA5:ITGB1 (Integrin α5β1)αVβ3 (Integrin αVβ3)NCL (Nucleolin)CTNNB1 (Beta-catenin)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on Endostar + chemotherapy (Simcere Pharmaceutical Group, 4c880a).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Endostar + chemotherapy (Simcere Pharmaceutical Group, 4c880a).